ABSTRACT
Importantly as our efforts to treat patients with CML improve in the TKI era, the prevalence of the disease has increased: if the annual death rate is around 2%, this predicts 250,000 CML patients in USA by 2030 (Fig. 4.1A); similar estimates have been predicted for CML patients in Europe (Fig. 4.1B). Clearly if the annual death rate is now around 1%, as many CML specialists believe it to be so, then this predicts 500,000 CML patients by 2030!
